Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study

DOI: https://doi.org/10.2147/ccid.s464326

2024-05-07

Clinical Cosmetic and Investigational Dermatology

Abstract:Matteo Megna, &ast Angelo Ruggiero, &ast Nello Tommasino, Claudio Brescia, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy &astThese authors contributed equally to this work Correspondence: Luca Potestio, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, 80131, Italy, Tel +39 - 081 – 7462457, Fax +39 - 081 – 7462442, Email Tildrakizumab is a humanised IgG1/k-type monoclonal antibody that targets the p19 protein subunit of IL23. Despite its effectiveness and safety have been widely reported by clinical trials and real-life experiences, data regarding its use on patients who previously failed anti-IL17 (brodalumab, ixekizumab, bimekizumab and/or secukinumab) are scant. Therefore, further studies on this topic would be beneficial for clinicians in guiding the selection of biologic shifting, considering that anti-IL23, − 12/23, and -IL17 partially share their therapeutic targets. In this context, we performed a 28-week, single-center, real-life, retrospective study, with the aim of assessing the efficacy and safety of tildrakizumab in patients who previously failed anti-IL17, also focusing the attention on psoriasis located in difficult-to-treat areas (scalp, palms or soles, fingernails, genitals). A total of 23 patients (12 male, 52.2%; mean age 52.8 ± 12.4 years) were enrolled. Of these, 11 (47.8%) failed secukinumab, 7 (30.4%) ixekizumab, 3 (13.0%) brodalumab, 1 (4.3%) both secukinumab and ixekizumab and 1 (4.3%) bimekizumab. At baseline, mean PASI and BSA were 12.8 ± 5.9 and 18.7 ± 9.6, respectively. At W16 PASI75 and PASI90 response were achieved by 15 (65.2%), and 9 (39.1%) patients, respectively, whereas 19 (82.6%) and 13 (56.6%) subjects reached these scores at W28. One (4.3%) case of primary inefficacy and 1 (4.3%) case of secondary inefficacy were assessed. Finally, no severe adverse events were collected. Tildrakizumab seems to be a valuable option in selected patients with psoriasis unresponsive to anti-IL17, suggesting that prior exposure to biological therapies seem not directly affect its effectiveness. Keywords: Tildrakizumab, psoriasis, real-life, anti-IL23 Psoriasis, a chronic inflammatory skin condition, affects approximately 3% of the global population. 1 Plaque psoriasis, the most prevalent form (up to 90% of cases), presents with distinct erythematous plaques primarily on areas like elbows, knees, lower back, scalp, and umbilicus, although it can affect any skin surface. 2 Psoriasis often coexists with various conditions such as psoriatic arthritis (PsA), inflammatory bowel diseases, metabolic syndrome, type 2 diabetes, cardiovascular disorders, and psychiatric illnesses. 3 Given these factors, an effective treatment strategy is essential, not only addressing the skin symptoms but also managing psoriatic disease comprehensively. 3 Globally, mild forms of psoriasis are often well-controlled with the use of topical treatments, mainly calcipotriol/betamethasone. 4,5 However, the management of moderate-to-severe forms may be challenging as the use of conventional systemic drugs (acitretin, ciclosporin, methotrexate, and dimethyl fumarate) can be contraindicated for the presence of comorbidities or the development of adverse events (AEs). 4,5 Recent knowledge on psoriasis pathogenesis, particularly on the role of interleukin (IL)23–Th17 axis, led to the development of new selective drugs. 6 Among these, tildrakizumab is a humanised IgG1/k-type monoclonal antibody that targets the p19 subunit of IL23, currently approved for the management of adult patients with moderate-to-severe plaque psoriasis. 7 Despite its efficacy and safety have been widely reported in literature, data regarding its use on patients who previously failed anti-IL17 are scant. 8–15 Therefore, further studies on this topic would be beneficial for clinicians in guiding the selection of biologic shifting, considering that anti-IL23, 12/23, and IL17 partially share their therapeutic targets. 16 In this context, we performed a 28-week, single-center, real-life, retrospective study, with the aim of assessing the efficacy and safety of tildrakizumab in patients who previously failed anti-IL17. Furthermore, the secondary outcome of our study was to investigate the effectiveness of tildrakizumab use following anti-IL17 failure in the so-called "difficult-to-treat areas" (scalp, genitals, palms and soles, fingernails), which are usually characterized by treatment resistance, as well as a strong impact on patients' quality of life. A monocentric retrospective study enrolling patients affected by -Abstract Truncated-

dermatology